Steffen Wedel

1.0k total citations
22 papers, 722 citations indexed

About

Steffen Wedel is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Steffen Wedel has authored 22 papers receiving a total of 722 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 11 papers in Pulmonary and Respiratory Medicine and 8 papers in Oncology. Recurrent topics in Steffen Wedel's work include Prostate Cancer Treatment and Research (9 papers), Histone Deacetylase Inhibitors Research (8 papers) and Protein Degradation and Inhibitors (5 papers). Steffen Wedel is often cited by papers focused on Prostate Cancer Treatment and Research (9 papers), Histone Deacetylase Inhibitors Research (8 papers) and Protein Degradation and Inhibitors (5 papers). Steffen Wedel collaborates with scholars based in Germany, United Kingdom and United States. Steffen Wedel's co-authors include Roman A. Blaheta, Eva Juengel, Lukasz Hudak, Dietger Jonas, Jon Jones, Axel Haferkamp, Igor Tsaur, Christoph Wiesner, Jürgen Hofmann and Arvind K. Virmani and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and International Journal of Cancer.

In The Last Decade

Steffen Wedel

21 papers receiving 711 citations

Peers

Countries citing papers authored by Steffen Wedel

Since Specialization

Citations

This map shows the geographic impact of Steffen Wedel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steffen Wedel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steffen Wedel more than expected).

Fields of papers citing papers by Steffen Wedel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steffen Wedel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steffen Wedel. The network helps show where Steffen Wedel may publish in the future.

Co-authorship network of co-authors of Steffen Wedel

This figure shows the co-authorship network connecting the top 25 collaborators of Steffen Wedel. A scholar is included among the top collaborators of Steffen Wedel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steffen Wedel. Steffen Wedel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study 2015 ·Journal for ImmunoTherapy of Cancer ·Hubert Kübler, Birgit Scheel, Ulrike Gnad-Vogt, Kurt Miller, Wolfgang Schultze‐Seemann, F. vom Dorp, Giorgio Parmiani, Christian Hampel, Steffen Wedel, Lutz Trojan, D. Jocham, Tobias Maurer, Gerd Rippin, Mariola Fotin‐Mleczek, (unknown), Jochen Probst, Ingmar Hoerr, Karl‐Josef Kallen, (unknown), Arnulf Stenzl	211
2	A Randomised Phase 2 Study Combining LY2181308 Sodium (Survivin Antisense Oligonucleotide) with First-line Docetaxel/Prednisone in Patients with Castration-resistant Prostate Cancer 2013 ·European Urology ·Paweł Wiechno, Bradley G. Somer, Begoña Mellado, Piotr Chłosta, (unknown), Daniel Castellano, Christoph Reuter, Michael Stöckle, Jörn Kamradt, Joanna Pikiel, Ignacio Durán, Steffen Wedel, Sophie Callies, Valérie André, Karla Hurt, Jacqueline Brown, Michael Lahn, Bernhard Heinrich	50
3	Low dosed interferon alpha augments the anti‐tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion 2012 ·The Prostate ·Lukasz Hudak, (unknown), Steffen Wedel, Jasmina Makarević, Eva Juengel, Igor Tsaur, Georg Bartsch, Christoph Wiesner, Axel Haferkamp, Roman A. Blaheta	21
4	Chemokines involved in tumor promotion and dissemination in patients with renal cell cancer 2012 ·Cancer Biomarkers ·Igor Tsaur, (unknown), Ana Maria Waaga-Gasser, Jasmina Makarević, L. Schmitt, M. Kurosch, (unknown), Christoph Wiesner, Steffen Wedel, Georg Bartsch, Hanns Ackermann, Elsie Oppermann, Maria Lazariotou, Martin Gasser, Axel Haferkamp, Roman A. Blaheta	7
5	Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells 2011 ·Clinical & Experimental Metastasis ·Steffen Wedel, Lukasz Hudak, (unknown), Jasmina Makarević, Eva Juengel, Igor Tsaur, Christoph Wiesner, Axel Haferkamp, Roman A. Blaheta	47
6	Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis 2011 ·BMC Cancer ·Steffen Wedel, Lukasz Hudak, (unknown), Jasmina Makarević, Eva Juengel, Igor Tsaur, Ana Maria Waaga-Gasser, Axel Haferkamp, Roman A. Blaheta	24
7	Association of Intravesical Tumor Location With Metastases to the Pelvic Lymph Nodes in Transitional Cell Cancer of the Bladder 2010 ·The American Journal of the Medical Sciences ·Steffen Wedel, Jon Jones, Igor Tsaur, Wolf‐Dietrich Beecken, Dietger Jonas, Roman A. Blaheta, Hanns Ackermann	9
8	Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells 2010 ·Cancer Letters ·Steffen Wedel, Lukasz Hudak, (unknown), Eva Juengel, Igor Tsaur, Axel Haferkamp, Roman A. Blaheta	16
9	Makrohämaturie als Primärsymptom eines extramedullären IgM-Plasmozytoms der Harnblase 2010 ·Der Urologe ·Igor Tsaur, M. Probst, Kai Uwe Chow, Christoph Renné, (unknown), (unknown), Eva Juengel, Steffen Wedel, (unknown), (unknown)	0
10	Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer 2010 ·The Prostate ·Steffen Wedel, Lukasz Hudak, (unknown), Eva Juengel, Elsie Oppermann, Axel Haferkamp, Roman A. Blaheta	11
11	Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001 2010 ·Life Sciences ·Steffen Wedel, Lukasz Hudak, (unknown), Eva Juengel, Igor Tsaur, Christoph Wiesner, Axel Haferkamp, Roman A. Blaheta	31
12	Präklinische Studien zum Einfluss des Tyrosinkinaseinhibitors AEE788 auf die Malignität des Nierenzellkarzinoms 2008 ·Der Urologe ·Steffen Wedel, (unknown), Eva Juengel, Janice Jones, Lukasz Hudak, Dietger Jonas, Roman A. Blaheta	2
13	The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo 2008 ·Journal of Cellular and Molecular Medicine ·Jon Jones, Eva Juengel, (unknown), Lukasz Hudak, Steffen Wedel, Dietger Jonas, Roman A. Blaheta	52
14	New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma 2008 ·Journal of Cellular and Molecular Medicine ·Steffen Wedel, Anna Sparatore, Piero Del Soldato, S-E. Al-Batran, Akin Atmaca, Eva Juengel, Lukasz Hudak, Dietger Jonas, Roman A. Blaheta	31
15	Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix 2008 ·Journal of Cellular and Molecular Medicine ·Jon Jones, Eva Juengel, (unknown), Lukasz Hudak, Steffen Wedel, Dietger Jonas, Gudrun Hintereder, Roman A. Blaheta	15
16	CXC chemokine mRNA expression as a potential diagnostic tool in prostate cancer 2008 ·Molecular Medicine Reports ·(unknown), Jon Jones, Eva Juengel, Tobias Engl, Dietger Jonas, Roman A. Blaheta, Steffen Wedel	12
17	Autocrine stimulation of human hepatocytes triggers late DNA synthesis and stabilizes long-term differentiation in vitro 2008 ·International Journal of Molecular Medicine ·(unknown), Christoph W. Strey, Wolf O. Bechstein, Kim Alexander Boost, Marcus Auth, (unknown), Eva Juengel, Steffen Wedel, Jon Jones, Dietger Jonas, Roman A. Blaheta	1
18	CXCR4 chemokine receptor engagement modifies integrin dependent adhesion of renal carcinoma cells 2007 ·Experimental Cell Research ·Jon Jones, (unknown), (unknown), Tobias Engl, Steffen Wedel, Borna Relja, Dietger Jonas, Roman A. Blaheta	41
19	Transient down‐regulation of beta1 integrin subtypes on kidney carcinoma cells is induced by mechanical contact with endothelial cell membranes 2007 ·Journal of Cellular and Molecular Medicine ·Jon Jones, (unknown), (unknown), Tobias Engl, Steffen Wedel, Borna Relja, Dietger Jonas, Roman A. Blaheta	12
20	Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer 1996 ·International Journal of Cancer ·Ulrich Kaiser, Jürgen Hofmann, (unknown), (unknown), (unknown), Steffen Wedel, Arvind K. Virmani, Ellen Wollmer, D. Branscheid, Adi F. Gazdar, K. Havemann	122

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact